Savara
Tracked across 4 events · 25 articles · First seen Sep 18, 2025 · Last active Jun 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Savara is facing a class action lawsuit for allegedly issuing materially false and/or misleading statements regarding its drug MOLBREEVI BLA, which could lead to financial losses for the company and its shareholders.
Sep 18, 2025 · 6 articles
Regulatory
Impact: Savara is the target of a class action lawsuit due to alleged misrepresentations regarding its MOLBREEVI Biologics License Application, which led to a significant drop in its stock price.
Oct 06, 2025 · 6 articles
Business
Impact: Savara Inc. is the target of a class action securities lawsuit due to alleged false statements and concealment regarding its MOLBREEVI BLA, leading to investor losses.
Oct 06, 2025 · 6 articles
Business
Impact: Savara announced a transition in its Chief Financial and Administrative Officer role, with Dave Lowrance stepping down and Bob Lutz assuming the CFO position. This change aims to ensure continued strong financial stewardship and operational leadership for the company.
Jun 08, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Savara live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard